Kalaris Posts $11.5M Q2 Loss, Cash Runway Into Q4 2027; Phase 1b/2 Data Due 1H 2027
KLRS sits 100% above its 52-week low of $2.14 on light trading volume (0.2× avg).
Summary
Kalaris reported Q2 2026 financials with a net loss of $11.5 million, nearly flat year-over-year, narrowing on lower administrative costs. Cash stands at $93.5 million, down from $118 million at year-end 2025, but management expects it to fund operations into Q4 2027 — past key clinical milestones. The Phase 1b/2 study of TH103 in wet AMD is now dosing patients, with preliminary data expected in the first half of 2027. Potential Phase 3 trials remain on track for initiation by year-end 2027. This follows the July 17 expanded Phase 1a data release that showed durable vision improvements and a clean safety profile. The cash runway extension and clinical timeline updates provide clarity on the path forward, though the company remains pre-revenue with ongoing cash burn.
At the time of this announcement, KLRS was trading at $4.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86M. The 52-week trading range was $2.14 to $11.88. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.